Moleculin Biotech risks Nasdaq delisting after shares stay below $1 bid threshold
MBRX•Nasdaq issues staff determination over bid-price rule
Moleculin Biotech received a Nasdaq staff determination letter on Sept. 15, 2026, flagging noncompliance with the $1 minimum bid rule.
Shares closed below $1 for 30 straight business days from July 31, 2026 through Sept. 11, 2026.
Nasdaq denied the standard 180-day cure period due to a 1-for-25 reverse split on Dec. 1, 2025.
A timely hearing request will stay any suspension or delisting while the Nasdaq panel reviews the case.
Continued listing remains uncertain if the stock fails to regain and hold the $1 bid threshold.
